Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder marked by amyloid-β accumulation, tau dysfunction, and neuroinflammation, involving endothelial cells and leukocytes. The breakdown of the blood-brain barrier allows immune cell infiltration, intensifying inflammation. A decreased ratio of Connexin-37 (Cx37, also known as GJA4: Gap Junction Protein Alpha 4) and Prolyl Hydroxylase Domain-Containing Protein 3 (PHD3, also known as EGLN3: Egl-9 Family Hypoxia Inducible Factor 3), Cx37/PHD3, consistently observed in different AD-related models, may represent a novel potential biomarker of AD, albeit the exact mechanisms underlying this phenomenon, most likely based on gap junction-mediated cellular interaction that modulate the cellular metabolite status, remain to be fully elucidated.
Original language | English (US) |
---|---|
Pages (from-to) | 1685-1687 |
Number of pages | 3 |
Journal | Journal of Alzheimer's Disease |
Volume | 97 |
Issue number | 4 |
DOIs | |
State | Published - Feb 13 2024 |
Keywords
- Alzheimer's disease
- Cx37
- PHD3
- blood-brain barrier
- endothelial cells
- inflammation
ASJC Scopus subject areas
- General Neuroscience
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health